Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Boulet

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Journal of Infectious Diseases|June 11, 2009
Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119)Jean-Michel Molina, Yves Levy, Isabelle Fournier, et al.
Future Oncology (London, England)|November 16, 2022
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancerSara A Hurvitz, Thomas Bachelot, Giampaolo Bianchini, et al.
The Oncologist|November 27, 2009
CXCR4 expression in early breast cancer and risk of distant recurrenceFabrice Andre, Weiya Xia, Rosa Conforti, et al.
Clinical Breast Cancer|June 3, 2025
Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II StudyJoyce O'Shaughnessy, Susana Sousa, Josefina Cruz, et al.
NPJ Breast Cancer|September 18, 2022
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINESibylle Loibl, Chiun-Sheng Huang, Max S Mano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN StudyIan E Krop, Seock-Ah Im, Carlos Barrios, et al.
The New England Journal of Medicine|January 15, 2025
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast CancerCharles E Geyer, Michael Untch, Chiun-Sheng Huang, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Journal of Infectious Diseases|June 11, 2009
Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119)Jean-Michel Molina, Yves Levy, Isabelle Fournier, et al.
Future Oncology (London, England)|November 16, 2022
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancerSara A Hurvitz, Thomas Bachelot, Giampaolo Bianchini, et al.
The Oncologist|November 27, 2009
CXCR4 expression in early breast cancer and risk of distant recurrenceFabrice Andre, Weiya Xia, Rosa Conforti, et al.
Clinical Breast Cancer|June 3, 2025
Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II StudyJoyce O'Shaughnessy, Susana Sousa, Josefina Cruz, et al.
NPJ Breast Cancer|September 18, 2022
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINESibylle Loibl, Chiun-Sheng Huang, Max S Mano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN StudyIan E Krop, Seock-Ah Im, Carlos Barrios, et al.
The New England Journal of Medicine|January 15, 2025
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast CancerCharles E Geyer, Michael Untch, Chiun-Sheng Huang, et al.
Pageof 2